Clinical Trial Update: A Prospective, Single-arm Clinical Study of Pabrolizumab in Combination With Cisplatin + 5-FU for the Neoadjuvant Treatment of Unresectable, Advanced Squamous Carcinoma of the Temporal Bone Single-arm Clinical Study [Phase 4]

View source ↗

Summary

A prospective, single-arm Phase 4 trial evaluating pabrolizumab with cisplatin and 5-FU as neoadjuvant therapy for unresectable, advanced temporal bone squamous…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Temporal Bone Squamous Cell Carcinoma

Drugs mentioned

• 5-FU (5-fluorouracil)
• CISPLATIN (cisplatin)
• pabrolizumab (pabrolizumab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Temporal Bone Squamous Cell Carcinoma | Phase 4 | Status: UNKNOWN